Ten patients with BRAF-WT and NRAS-WT melanoma received the pasireotide treatment….Among the total 10 patients included in the study, the best ORR (defined as PR or better) was observed in one (10%) patient (95% CI 0.3 to 44.5), and best overall DCR (defined as stable disease or better) was observed in two (20%) patients (95% CI 2.5 to 55.6), both by CT or MRI and 18-FDG-PET. Stable disease and PR were observed in one patient each. The best ORR for patients with the measurable disease at baseline is presented in (online supplementary table 1)....Pasireotide was well tolerated, and safety results were similar to those previously reported in other indications.